Cyclacel Pharmaceuticals, Inc. (BGMS) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cyclacel Pharmaceuticals, Inc. (BGMS:NASDAQ), powered by AI.
- Current Price
- $1.50
- P/E Ratio
- -1.1
- Market Cap
- 3M
- Sector
- Healthcare
What is the Cyclacel Pharmaceuticals, Inc. stock price forecast?
Cyclacel Pharmaceuticals, Inc. is currently trading at $1.50. View real-time AI analysis on Alpha Lenz.
What is Cyclacel Pharmaceuticals, Inc. insider trading activity?
View the latest insider trading data for Cyclacel Pharmaceuticals, Inc. on Alpha Lenz.
What is Cyclacel Pharmaceuticals, Inc.'s P/E ratio?
Cyclacel Pharmaceuticals, Inc.'s P/E ratio is -1.1.
Cyclacel Pharmaceuticals, Inc.
NASDAQ · BGMS“Cyclacel Pharmaceuticals, Inc. trades at a P/E of -1.1 (undervalued) with modest ROE of -128.4%.”
Ask for details →Company Overview
Bio Green Med Solution, Inc. engages in the distributing, trading, and installation of protective and fire safety materials and equipment, and fire protection and prevention systems. It also researches and develops pharmaceuticals. The company was formerly known as Cyclacel Pharmaceuticals, Inc. and changed its name to Bio Green Med Solution, Inc. in September 2022. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Cyclacel Pharmaceuticals, Inc. trades at a P/E of -1.1 (undervalued) with modest ROE of -128.4%.”
Ask for details →Frequently Asked Questions
Cyclacel Pharmaceuticals, Inc. (ticker: BGMS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). Market cap is $3M.
The current price is $1.5 with a P/E ratio of -1.09x and P/B of 0.48x.
ROE is -128.45% and operating margin is -1128.11%. Annual revenue is $747,000.